Target 3.d: Early warning and risk management for health
Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks
Owners voting their values help. Others must carry most of it.
Why shareholder democracy is helpful
Surveillance and emergency-response capacity are state functions coordinated by WHO. The COVID-19 experience showed that managing a global health risk also depends on vaccine and therapeutic manufacturers' willingness to share technology and price for access. ICCR's 2021 proposals at Pfizer, Johnson and Johnson and Merck asked how nearly 2 billion dollars of US public funding to Pfizer and BioNTech and NIH-funded mRNA research would shape access strategies. The Access to Medicine Index continues to urge Pfizer to extend technology transfer beyond COVID-19 vaccines. Owners therefore help at the margin on the manufacturing and access side of risk management, not on early warning itself.
How this was scoredHelpful
Helpful. Owners voting their values help. Others must carry most of it.
We have not yet written down the two answers behind this rating. Recording them on every item, so a reader can check the reasoning and not only the conclusion, is work in progress.
Every rating is the higher of two answers, one for what companies do and one for what they spend to stop the outcome, because the same vote reaches both. See the full method.
Sources
What civil society organizations are helping owners on this
Coordinated member resolutions at Johnson and Johnson, Merck and Pfizer asking how government funding for COVID-19 vaccines and therapeutics was being reflected in company access and pricing strategies.
Filed the proposal at Johnson and Johnson asking the company to report on whether and how public financial support shapes its access strategy for COVID-19 products.
2 campaigns on record
Disclose whether and how government financial support for research, development and manufacturing is considered in setting access and pricing strategies for COVID-19 vaccines and treatments.
With Seventh Generation Interfaith Coalition for Responsible Investment, Trinity Health
Result: not stated in source
Report on whether and how government financial support is being or will be considered in developing the company's access strategies for COVID-19 vaccines and therapeutics, including pricing.
Result: not stated in source
How this rating was made
Every item on every one of our maps is read against one question: how far does this depend on the people who own companies voting their values? We answer it twice, once for what companies do and once for what they spend to stop the outcome, and take whichever answer is higher, since the same vote reaches both. The score carries its reasoning and its sources so that a reader can check it rather than take it.
- Pivotal. Owners voting their values can deliver most of the outcome.
- Necessary. Owners remove an obstacle nothing else removes, and others must also act.
- Helpful. Owners voting their values help, and others carry most of it.
- Independent. This moves without owners. Other levers carry it.
The advocacy record on this page holds only what a source we opened says happened. Where we searched and found nothing, the page says so rather than leaving a silence. Where a campaign names a filer the source does not name, it says that too. Ratings are ours; the list of subjects is UN Sustainable Development Goals's, and we link to their original.
How we score dependency, in full.